TherapeuticsMD (NASDAQ:TXMD) is a women’s healthcare company focused on developing, manufacturing and commercializing novel therapies for conditions that affect women throughout their lives. The company’s primary business activities center on delivering prescription products to address menopause symptoms and hormone-related disorders, with a portfolio that includes both oral and vaginal formulations. TherapeuticsMD emphasizes the clinical and patient experience, aiming to improve convenience, safety and adherence through targeted delivery systems and differentiated dosing options.
The company’s lead marketed products include Bijuva, an oral capsule combining bio-identical estradiol and progesterone designed to treat moderate-to-severe vasomotor symptoms associated with menopause, and Imvexxy, a low-dose vaginal estradiol insert for the treatment of dyspareunia and other genitourinary symptoms of menopause. Both products leverage the company’s proprietary formulation technologies, which aim to provide consistent hormone release while minimizing systemic exposure. TherapeuticsMD also maintains a pipeline of additional menopausal hormone therapy candidates and related women’s health assets in various stages of clinical development.
Founded in 2009 and headquartered in Boca Raton, Florida, TherapeuticsMD went public in 2014 and has since grown through internal development and strategic licensing acquisitions. In 2017, the company completed a license transaction to acquire U.S. rights to Bijuva and Imvexxy from a global healthcare partner, strengthening its commercial footprint. Research and development activities are carried out in collaboration with specialty pharmaceutical manufacturers and contract research organizations, while commercialization is supported by a dedicated sales force, medical affairs and reimbursement teams.
TherapeuticsMD’s leadership team is led by Chief Executive Officer Robert Azelby, who co-founded the company and has overseen its evolution into a women’s health specialist. The executive team combines experience in regulatory affairs, clinical development, commercial operations and finance. TherapeuticsMD’s operations are primarily focused on the United States, where it seeks to expand access to its products through direct partnerships with healthcare providers, specialty pharmacies and payers, with the goal of addressing the unmet needs of women undergoing hormonal transitions.
